Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SLXP > SEC Filings for SLXP > Form 8-K on 24-Apr-2014All Recent SEC Filings

Show all filings for SALIX PHARMACEUTICALS LTD

Form 8-K for SALIX PHARMACEUTICALS LTD


24-Apr-2014

Other Events, Financial Statements and Exhibits


Item 8.01. Other Events.

On April 22, 2014, Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals, Inc. announced that the submission to the European Medicines Agency of Relistor® (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, had been accepted for review. If approved, this will add to the current marketing authorization in the European Union, which allows for the use of Relistor in advanced illness patients.

A copy of the press release issued by Salix Pharmaceuticals, Ltd. and Progenics Pharmaceuticals, Inc. announcing this development is attached hereto as Exhibit 99.1.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No. Description

99.1 Press release dated April 22, 2014.


  Add SLXP to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SLXP - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.